UNSPSC 51182412: Tribasic calcium phosphates

This classification denotes a form of tricalcium phosphate are used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP), with the molecular formula 5CA.3O4P.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91D9GV0Z28.

European Medicines Agency schedules tribasic calcium phosphatein its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34727. The term tribasic calcium phosphate is Homeopathic Pharmacopoeia of the United States designation.

UNSPSC 51182412 Tribasic calcium phosphates, a Commodity code, describes chemical compounds used in pharmaceutical and nutritional formulations that state and local health systems and cooperative purchasing alliances procure as finished pharmaceutical products and over-the-counter medications. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and similar multi-state and state procurement offices issue solicitations under this code to establish supply contracts with pharmaceutical manufacturers capable of meeting cGMP standards, FDA compliance, and Drug Supply Chain Security Act (DSCSA) certification. The scope of work encompasses sourcing of generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, with vendors required to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), provide detailed product data including NDC codes and SKUs, and offer flexible pricing structures such as flat price, net price formats (NF30, NF60, NF90), or WAC-minus arrangements. Issuing bodies are primarily state procurement offices administering cooperative purchasing agreements that span multiple states and local government members.

Recent activity centers on the Minnesota Department of Administration's multi-state cooperative vehicle. MMCAP issued Request for Proposal S1070000015802 on January 20, 2026, with proposals due March 26, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution across Minnesota, Oregon, and other participating member jurisdictions. Evaluation criteria weight price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Contract awards are effective July 1, 2026, with a two-year initial term and optional extensions; incumbent vendor amendments extend through June 30, 2028. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence and maintain professional liability of $2,000,000, with all products requiring FDA compliance, a minimum one-year expiration date from manufacture, and six-month shelf life.